

PROVECTUS BIOPHARMACEUTICALS, INC.  
Form SC TO-I/A  
March 31, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**SCHEDULE TO/A**

**(Final Amendment)**

**(Rule 13e-4)**

**TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**PROVECTUS BIOPHARMACEUTICALS, INC.**

**(Name of Subject Company and Filing Person (Issuer))**

**Warrants to Purchase Common Stock**

**(Title of Class of Securities)**

**74373P108**

**(CUSIP Number of Common Stock Underlying Warrants)**

**Peter R. Culpepper**

**Provectus Biopharmaceuticals, Inc.**

**7327 Oak Ridge Highway, Suite A**

**Knoxville, TN 37931**

**(866) 594-5999**

**(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)**

*With copies to:*

**Tonya Mitchem Grindon, Esq.**

**Lori B. Metrock, Esq.**

**Baker Donelson Bearman Caldwell & Berkowitz PC**

**211 Commerce St., Suite 800**

**Nashville, TN 37201**

**Telephone: (615) 726-5600**

**December 31, 2015**

**(Date Tender Offer First Published, Sent or Given to Security Holders)**

### **CALCULATION OF FILING FEE**

**Transaction Valuation<sup>(1)</sup>**  
**\$15,531,092.37**

**Amount of Filing Fee<sup>(2)</sup>**  
**\$1,563.98**

- (1) Estimated for purposes of calculating the amount of the filing fee only. The transaction valuation is calculated pursuant to Rule 0-11(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), as the product of 59,861,601 and \$0.25945. The transaction valuation assumes the tender of 59,861,601 warrants to purchase shares of common stock, which were issued between January 6, 2011 and November 1, 2015 (the Existing Warrants) by the Existing Warrant holders as a result of this tender offer and was determined by using the average of the high and low prices of Provectus Biopharmaceuticals, Inc. warrants reported on the NYSE MKT as of December 28, 2015, which was \$0.25945.
- (2) The amount of filing fee is calculated pursuant to Rule 0-11(d) of the Exchange Act. The filing fee equals \$100.70 for each \$1,000,000 of the value of the transaction, and was calculated as the product of the transaction valuation of \$15,531,092.37 multiplied by 0.0001007.

Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC. - Form SC TO-1/A

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$11,212.20.

Filing Party: Provectus Biopharmaceuticals, Inc.

Form or Registration No.: Registration Statement on Form S-4. Date Filed: December 31, 2015.

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

- third-party tender offer subject to Rule 14d-1.
- issuer tender offer subject to Rule 13e-4.
- going-private transaction subject to Rule 13e-3.
- amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

This Final Amendment (this Final Amendment ) relates to the Tender Offer Statement on Schedule TO (the Schedule TO ) originally filed with the Securities and Exchange Commission ( SEC ) by Provectus Biopharmaceuticals, Inc. (the Company ), a Delaware corporation, on December 31, 2015, and as amended and supplemented by Amendment No. 1 to the Schedule TO filed with the SEC on February 12, 2016, Amendment No. 2 to the Schedule TO filed with the SEC on March 7, 2016 and Amendment No. 3 to the Schedule TO filed with the SEC on March 22, 2016. This Schedule TO relates to an offer by the Company to holders of 59,861,601 unregistered warrants to purchase the Company s common stock that were issued between January 6, 2011 and November 1, 2015 (the Existing Warrants ). Capitalized terms used herein but not otherwise defined have the meanings set forth in the Schedule TO.

The Offer temporarily modified the terms of such Existing Warrants so that each holder who tendered Existing Warrants during the offering period for early exercise was able to do so at a discount on the exercise price equal to \$0.50 per share (Existing Warrants currently have exercise prices ranging from \$1.00 to \$3.00 per share), and received, in addition to the shares of common stock purchased upon such exercise, new warrants to purchase an equal number of shares of the Company s common stock at an exercise price of \$0.85 per share that will expire June 19, 2020 (the Replacement Warrants ).

This Final Amendment is being filed to report the results of the Offer and is intended to satisfy the reporting requirements of Rule 13e-4(c)(4) promulgated under the Exchange Act:

1. The Offer expired at 4:00 p.m., Eastern Time, on March 28, 2016.
2. In accordance with the terms and conditions of the Offer, and based on the final count by Broadridge Corporate Issuer Solutions, Inc. ( Broadridge ), the depository, 7,798,507 Existing Warrants were validly tendered and not withdrawn prior to the expiration of the Offer.
3. The Company accepted for purchase approximately 7,798,507 Existing Warrants properly tendered and not properly withdrawn prior to the expiration of the Offer.
4. All tendered Existing Warrants were retired effective as of the expiration of the Offer Period.
5. The Company will promptly delivery 7,798,507 shares of Common Stock and 7,798,507 Replacement Warrants, along with certificates representing the balance of the unexercised portions of tendered Existing Warrants.

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PROVECTUS BIOPHARMACEUTICALS,  
INC.

By /s/ Peter R. Culpepper  
Peter R. Culpepper  
Interim Chief Executive Officer, Chief  
Financial Officer, Chief Accounting

Officer and Chief Operating Officer

Dated: March 31, 2016